Profit more than 45 million yuan Wang Yawei evacuate modern pharmacy

Also a listed company with a clear restructuring expectation, Wang Yawei's attitude towards modern pharmaceuticals in the two quarter is exactly the opposite of fuling power. According to the report, Wang Yawei's Huaxia market this year has gone from the top ten circulating shareholder list in modern pharmacy.　　However, in the last three quarters of the Wang Yawei has been settled from the profit of the bandits, the extent of about 50%. The huge reorganization imagination space according to the modern pharmaceutical bulletin shows that the company achieved net profit of 48.706 million yuan in the first half of this year, an increase of 45.04%, the basic earnings per share reached 0.17 yuan.　　The company said that this is mainly because the company during the reporting period to increase market expansion, and actively create new products.　　However, for modern pharmaceuticals, its future strong asset restructuring is expected to be the core cause of the market's high concern for the unit. In the reform, the large shareholder Shanghai Medical Engineering Institute has promised to inject high-quality assets into the listed companies. In recent years, Shanghai Hospital has also repeatedly reiterated the need to gradually inject assets, and even the overall listing. July 15 this year, modern pharmaceutical also announced that the company intends to acquire Shanghai Medical Engineering Institute Pharmaceutical Co., Ltd. (hereinafter referred to as "Shanghai Medicine"), the board is currently authorizing the management of the preliminary preparatory work for the acquisition. In this respect, some people in the industry have made it clear that this part of the asset performance in general, Shanghai Medical College subordinates also have a lot of quality assets. In particular, a large number of research and development assets.　　It is reported that management is very inclined to continue to talk about research and development assets into listed companies, until the overall listing. In addition, in April this year the State Council has approved the Shanghai Medical Engineering Institute as a whole to become its wholly-owned enterprises.　　It is reported that the future of the Chinese medicine group will be the former Shanghai medical institutions, the United Nations drug internal resources, the establishment of a central medical research platform, the development of a short board to supplement the long.　　This means that, as the Shanghai Medical Engineering Institute's listed platform, the future of modern pharmaceutical industry also has a strong asset consolidation expectations.　　Wang Yawei. However, facing the "big cake", which is expected to be released in the near future, Wang Yawei has chosen to cash in. According to the listed companies previously released data show that the third quarter of last year, Wang Yawei's Huaxia market to buy 6.5082 million shares, become its seventh largest circulating shareholder.　　According to the price of the unit at that time, the average cost of Wang Yawei is 10.97 yuan per share, and the total amount of money spent is 71.395 million yuan. Since last year, the stock prices of modern pharmaceuticals have been rising, and the rise of Wang Yawei has not changed.　　2009 years of the Four Seasons, Wang Yawei 196,000 shares, according to the average price of 13.85 yuan to calculate the current 2.7146 million yuan; in the first quarter of this year, the unit continued to rise, the period of sale of 15.51 Yuan, Wang Yawei again to lighten 2.8232 million shares, set now about 43.78 million yuan. According to the company's report, as at the end of the two quarter of this year, Wang Yawei in the other circulating shareholder shares without much change at the same time from the modern pharmaceutical top ten circulating shareholder list completely disappeared. In the two quarter of this year, the average price of 16.60 yuan, Wang YaweiIt is now 57.9157 million yuan. To sum up, Wang Yawei has been set to total about 104 million yuan, and its initial cost of investment compared to profit margin of about 46.24%. Whether or not modern pharmaceuticals has been carrying out large-scale asset restructurings since then, it has made a full profit.